Antibalder GHK-Cu + Minoxidil – 60 capsules

Antibalder — GHK-Cu + Minoxidil oral research capsules, combining two of the most extensively cited hair-cycle-modulating molecules in the dermatology literature into a single research formulation. GHK-Cu (the copper tripeptide-1 complex) is one of only two bioactive peptides explicitly recommended in published trichology consensus reviews. Minoxidil is, by a wide margin, the most studied small molecule in male and female pattern hair-loss research: more than 40 controlled trials, three decades of post-marketing data, and a well-characterized mechanism centered on follicular vasodilation and ATP-sensitive K⁺-channel opening. Antibalder pairs them in fixed unit doses to enable structured experimental work on combined-pathway hair-cycle modulation.

Research Overview

GHK (glycyl-L-histidyl-L-lysine) is a tripeptide naturally present in human plasma at micromolar concentrations, where it forms a high-affinity 1:1 complex with copper(II) — the bioactive form, GHK-Cu [1]. The complex modulates more than 4,000 human genes (over a third of the human genome) according to Connectivity-Map analyses, with a clear bias toward tissue-remodeling, anti-inflammatory and anti-aging programs; in dermal papilla cells specifically, GHK-Cu upregulates VEGF, FGF-7 and noggin and prolongs anagen [1]. Minoxidil — originally developed as an antihypertensive — is the gold-standard topical and oral drug in pattern hair loss; its sulfate metabolite opens vascular ATP-sensitive K⁺ channels and dramatically upregulates VEGF in dermal papilla, prolonging anagen and shortening telogen [2,3]. Recent low-dose oral minoxidil literature has expanded the pharmacology beyond topical applications, with multiple controlled studies demonstrating efficacy at doses orders of magnitude below antihypertensive thresholds [3]. Antibalder enables researchers to study the combined effect of these two convergent vascular-and-trophic pathways in a single fixed-ratio formulation.

Primary Research Areas

• Hair cycle and dermal-papilla biology — the two best-characterized small-molecule/peptide tools for prolonging anagen and rescuing miniaturized follicles in research models [1,2].
• VEGF / vascular research in skin — both actives independently upregulate dermal-papilla VEGF, providing a clean two-pathway design for vascular-mediated trichogenesis studies [1,2].
• Wound healing and tissue remodeling — GHK-Cu has a long literature in skin wound healing, collagen organization and matrix metalloproteinase modulation [1].
• ATP-sensitive K⁺ channel pharmacology — minoxidil sulfate is the canonical opener of K-ATP channels in vascular smooth muscle and dermal papilla cells [2].
• Anti-inflammatory and anti-aging gene programs — GHK-Cu reproducibly resets Connectivity-Map signatures associated with cellular senescence and inflammaging [1].

References

1. Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. Int J Mol Sci. 2018;19(7):1987.
2. Messenger AG, Rundegren J. Minoxidil: mechanisms of action on hair growth. Br J Dermatol. 2004;150(2):186–194.
3. Randolph M, Tosti A. Oral minoxidil treatment for hair loss: a review of efficacy and safety. J Am Acad Dermatol. 2021;84(3):737–746.